Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
David Hoffman: BTC is at its 200-week moving average, and it's difficult to replicate an FTX-level systemic collapse in the current environment

David Hoffman: BTC is at its 200-week moving average, and it's difficult to replicate an FTX-level systemic collapse in the current environment

Odaily星球日报Odaily星球日报2026/06/04 13:33
Show original

According to Odaily, David Hoffman, co-founder of Bankless who previously announced a complete sell-off of ETH, shared his view that the current Bitcoin price is precisely sitting on the 200-week moving average (MA). Reviewing historical market trends, BTC only effectively broke below this moving average during the bear market phase triggered by the successive collapses of Terra, Three Arrows Capital, and FTX, which led to industry-wide liquidations and constituted some of the most destructive systemic crises in crypto industry history. In his opinion, the market risks posed by Michael Saylor’s Strategy introducing convertible bonds and related actions fall far short of the impact caused by those cascading blowups. He also disclosed his holding costs again: NEAR was accumulated at around $1.4, HYPE at about $45, and ZEC at approximately $560.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage